The evolving role of [¹⁸F]FDG PET/CT in reducing or replacing biopsy in selected malignancies: A narrative literature review.

[PURPOSE] This literature review aims to evaluate the current evidence regarding the potential of [¹⁸F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG PET/CT) to reduce or replace biopsy in specific oncologic settings. We examine the diagnostic performance of FDG PET/CT and the clinical scenarios where this imaging modality might appropriately substitute for invasive procedures.

[METHODS] This article is a narrative literature review. A literature search was conducted using the PubMed/MEDLINE and Google Scholar databases to identify relevant English-language articles, with a focus on publications from the last 10 years. The search was supplemented by a review of clinical guidelines and position statements from major oncology and nuclear medicine societies. The retrieved literature was synthesized to evaluate the evidence for [¹⁸F]FDG PET/CT as a potential replacement for biopsy in selected oncologic scenarios.

[RESULTS] The utility of FDG PET/CT as an alternative to biopsy varies significantly by cancer type and clinical context. The most substantial evidence supporting FDG PET/CT as a replacement for biopsy exists in the staging of lymphoma, where international guidelines endorse its use in place of bone marrow biopsy for Hodgkin lymphoma and most diffuse large B-cell lymphomas. In other areas, such as head and neck cancer of unknown primary, PET/CT serves to guide, rather than replace, biopsy. In recurrent colorectal and esophageal cancer, it plays a key role in avoiding futile major surgical interventions. In the management of indeterminate thyroid nodules, it has been shown to reduce unnecessary diagnostic surgeries.

[CONCLUSION] While biopsy remains the gold standard for initial cancer diagnosis, there are specific, guideline-endorsed clinical contexts in which [¹⁸F]FDG PET/CT can obviate the need for invasive tissue sampling, most notably in lymphoma staging. In selected high-confidence scenarios, such as treatment response assessment, suspected recurrence, and the evaluation of indeterminate lesions with high negative predictive value, FDG PET/CT may allow safe deferral or replacement of repeat biopsy. In many other clinical situations, its primary role is to guide invasive procedures to improve diagnostic yield and to prevent unnecessary or futile interventions. As imaging technology and radiotracers continue to evolve, the role of PET/CT in non-invasive tumor characterization and in selectively reducing or replacing biopsy is expected to expand.